Bambusa Therapeutics Reports Potentially Transformative Preliminary Proof-of-Concept Results for BBT001 in Atopic Dermatitis, Reinforcing Its Best-in-Disease Potential
PR Newswire
BOSTON, July 27, 2026
BBT001 delivered highly statistically significant and clinically meaningful improvement in EASI beginning at Week 1, with responses continuing to improve over timeFast-onset and potent itch relief was observed as early as Day 1 after the first dose alongside robust and durable suppression of Type 2 inflammatory biomarkersFavorable safety, extended half-life and low immunogenicity findings support BBT001's potential best-in-disease profile and infrequent maintenance dosingAdditional topline data from ongoing BBT001 studies in atopic dermatitis and chronic spontaneous urticaria expected in 1H 2027BOSTON, July 27, 2026 /PRNewswire/ -- Bambusa Therapeutics, Inc. (Bambusa Therapeutics or Bambusa), a clinical-stage biotechnology company developing next-generation, long-acting bispecific antibodies designed for immunology and inflammation (I&I), today announced compelling preliminary data of bio-naïve patients with moderate-to-severe atopic dermatitis (AD) who received four weeks of treatment in its ongoing global Phase 1 clinical trial of BBT001. BBT001 is a half-life-extended bispecific antibody targeting interleukin-4 receptor alpha (IL-4Rα) and interleukin-31 (IL-31).
